Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level of
care to the right patients at the right time. It represents an adaption of the Mount Sinai
PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. ...
Age: 18 years - 66+
Gender: All
First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial
with the goal of determining the safety of TheraSphere PCa device in patients with clinically
localized prostate cancer across US-based centers.
Age: 50 years - 66+
Gender: Male
Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening
The purpose of this research study is to evaluate the efficacy of a digital navigation tool,
called the eNav to improve colorectal cancer screening uptake among patients treated at
federally qualified health centers (FQHC)s. The digital navigation tool includes a we...
Age: 45 - 75 years
Gender: All
Mobile Ostomates Resources for Patients and Caregivers
The scope of this research is to examine the acceptability and feasibility of a refined web-based intervention ("STOMA Care" app) by conducting a randomized pilot consisting of bladder and colorectal cancer patients scheduled for ostomy surgery at Mount Sinai Health Sys...
Age: 21 years - 66+
Gender: All
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to...
Age: 18 years - 66+
Gender: All
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in
treating patients with localized prostate cancer. Participants will go through baseline and
follow up assessments up to 12 months.
Age: 40 years - 66+
Gender: Male
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and
paclitaxel combination therapy in patients with relapsed or refractory extensive stage small
cell lung cancer.
Age: 18 years - 66+
Gender: All
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend...
Age: 18 years - 66+
Gender: All
Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of
Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a
rare type of cancer that starts in the white blood cells and eventually can result in rashes
...
Age: 18 years - 66+
Gender: All
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in
cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The
Expansion Phase will begin in parallel one dose level lower than the highest dose deemed s...
Age: 18 years - 66+
Gender: All
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunother...
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a "study
drug" or collectively called "study drugs". 'Investigational' means that the study d...
Age: 18 years - 66+
Gender: All
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the
combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the
treatment of pre- and postmenopausal women and men who have previously received ribo...
Age: 18 years - 66+
Gender: All
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramuciruma...
Age: 18 years - 66+
Gender: All
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard
chemotherapy improves the efficacy compared to just chemotherapy alone in participants with
metastatic pancreatic cancer. One group of participants will only receive chemotherapy ...
Age: 18 years - 66+
Gender: All
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene (known...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course
chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs,
such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX
...
Age: 18 years - 66+
Gender: All
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced
non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due
to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radi...
Age: 18 years - 66+
Gender: All
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This randomized Phase 3 open-label study will compare the efficacy of the T-cell
immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT)
monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal
an...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All